Literature DB >> 18981158

The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells.

Anya Schneider1, Mary Rieck, Srinath Sanda, Catherine Pihoker, Carla Greenbaum, Jane H Buckner.   

Abstract

Defects in immune regulation have been implicated in the pathogenesis of diabetes in mouse and in man. In vitro assays using autologous regulatory (Treg) and responder effector (Teff) T cells have shown that suppression is impaired in diabetic subjects. In this study, we addressed whether the source of this defect is intrinsic to the Treg or Teff compartment of diabetic subjects. We first established that in type 1 diabetes (T1D) individuals, similar levels of impaired suppression were seen, irrespective of whether natural (nTreg) or adaptive Treg (aTreg) were present. Then using aTreg, we examined the ability of T1D aTreg to suppress Teff of healthy controls, as compared with the ability of control aTreg to suppress Teff of diabetic subjects. Taking this approach, we found that the aTregs from T1D subjects function normally in the presence of control Teff, and that the T1D Teff were resistant to suppression in the presence of control aTreg. This escape from regulation was seen with nTreg as well and was not transferred to control Teff coincubated with T1D Teff. Thus, the "defective regulation" in T1D is predominantly due to the resistance of responding T cells to Treg and is a characteristic intrinsic to the T1D Teff. This has implications with respect to pathogenic mechanisms, which underlie the development of disease and the target of therapies for T1D.

Entities:  

Mesh:

Year:  2008        PMID: 18981158      PMCID: PMC2597079          DOI: 10.4049/jimmunol.181.10.7350

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function.

Authors:  Angela M Thornton; Erin E Donovan; Ciriaco A Piccirillo; Ethan M Shevach
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

2.  Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes.

Authors:  Shelley Lindley; Colin M Dayan; Amanda Bishop; Bart O Roep; Mark Peakman; Timothy I M Tree
Journal:  Diabetes       Date:  2005-01       Impact factor: 9.461

3.  CD4+CD25high regulatory T cells in human autoimmune diabetes.

Authors:  Amy L Putnam; Francesco Vendrame; Francesco Dotta; Peter A Gottlieb
Journal:  J Autoimmun       Date:  2005-01-12       Impact factor: 7.094

4.  Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes.

Authors:  Todd M Brusko; Clive H Wasserfall; Michael J Clare-Salzler; Desmond A Schatz; Mark A Atkinson
Journal:  Diabetes       Date:  2005-05       Impact factor: 9.461

5.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.

Authors:  Mindi R Walker; Deborah J Kasprowicz; Vivian H Gersuk; Angele Benard; Megan Van Landeghen; Jane H Buckner; Steven F Ziegler
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

6.  Lymphocyte subset abnormalities, autoantibodies and their relationship with HLA DR types in children with type 1 (insulin-dependent) diabetes and their first degree relatives.

Authors:  M Peakman; T Warnock; A Vats; G L McNab; J Underhill; P T Donaldson; D Vergani
Journal:  Diabetologia       Date:  1994-02       Impact factor: 10.122

7.  Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127 -/low regulatory T cells in patients with active systemic lupus erythematosus.

Authors:  Ram Kumar Chowdary Venigalla; Theresa Tretter; Stefan Krienke; Regina Max; Volker Eckstein; Norbert Blank; Christoph Fiehn; Anthony Dick Ho; Hanns-Martin Lorenz
Journal:  Arthritis Rheum       Date:  2008-07

8.  Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development.

Authors:  Silvia Gregori; Nadia Giarratana; Simona Smiroldo; Luciano Adorini
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

9.  X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy.

Authors:  R S Wildin; F Ramsdell; J Peake; F Faravelli; J L Casanova; N Buist; E Levy-Lahad; M Mazzella; O Goulet; L Perroni; F D Bricarelli; G Byrne; M McEuen; S Proll; M Appleby; M E Brunkow
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

10.  In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes.

Authors:  Qizhi Tang; Kammi J Henriksen; Mingying Bi; Erik B Finger; Greg Szot; Jianqin Ye; Emma L Masteller; Hugh McDevitt; Mark Bonyhadi; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2004-06-07       Impact factor: 14.307

View more
  141 in total

Review 1.  New technologies for autoimmune disease monitoring.

Authors:  Holden T Maecker; Garry P Nolan; Charles G Fathman
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-08       Impact factor: 3.243

Review 2.  The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer.

Authors:  Frances Mercer; Derya Unutmaz
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

Review 3.  Genetics, pathogenesis and clinical interventions in type 1 diabetes.

Authors:  Jeffrey A Bluestone; Kevan Herold; George Eisenbarth
Journal:  Nature       Date:  2010-04-29       Impact factor: 49.962

4.  Beta cells under attack: toward a better understanding of type 1 diabetes immunopathology.

Authors:  Ken T Coppieters; Bart O Roep; Matthias G von Herrath
Journal:  Semin Immunopathol       Date:  2010-12-18       Impact factor: 9.623

Review 5.  Targeting memory T cells in type 1 diabetes.

Authors:  Mario R Ehlers; Mark R Rigby
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

6.  CD4 T cell-intrinsic role for the T helper 17 signature cytokine IL-17: Effector resistance to immune suppression.

Authors:  Michael P Crawford; Sushmita Sinha; Pranav S Renavikar; Nicholas Borcherding; Nitin J Karandikar
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-27       Impact factor: 11.205

7.  Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances.

Authors:  Simi Ahmed; Karen Cerosaletti; Eddie James; S Alice Long; Stuart Mannering; Cate Speake; Maki Nakayama; Timothy Tree; Bart O Roep; Kevan C Herold; Todd M Brusko
Journal:  Diabetes       Date:  2019-07       Impact factor: 9.461

Review 8.  The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation.

Authors:  Allison L Bayer; Alberto Pugliese; Thomas R Malek
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

9.  Increased islet antigen-specific regulatory and effector CD4+ T cells in healthy individuals with the type 1 diabetes-protective haplotype.

Authors:  Xiaomin Wen; Junbao Yang; Eddie James; I-Ting Chow; Helena Reijonen; William W Kwok
Journal:  Sci Immunol       Date:  2020-02-14

10.  Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression.

Authors:  Christian Hundhausen; Alena Roth; Elizabeth Whalen; Janice Chen; Anya Schneider; S Alice Long; Shan Wei; Rebecca Rawlings; MacKenzie Kinsman; Stephen P Evanko; Thomas N Wight; Carla J Greenbaum; Karen Cerosaletti; Jane H Buckner
Journal:  Sci Transl Med       Date:  2016-09-14       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.